Get All Access for $5/mo

CrisprBits Raises $250,000 in Pre-Seed Round from US-based VJ Group The funding will be utilized for product development, team expansion and for research and development

By Saptak Bardhan

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

CrisprBits

CrisprBits on Monday announced to have raised $250,000 in pre-seed funding from US-based VJ Group. The funding will be utilized for product development, team expansion and for research and development.

"CrisprBits was founded with an aim to address critical healthcare needs through the use of a breakthrough technology like CRISPR. The team's prior experience in developing diagnostics, precision medicine and clinical-research solutions that are used by clinicians, pharmaceutical and biotechnology companies in India and around the world, has enabled us to come out with products that have significant public health and social impact. The new investment will accelerate our next phase of growth and allow us develop many more high-quality healthcare solutions in diagnostics and gene editing," said Sunil Arora, co-founder and CEO, CrisprBits

"The potential of CRISPR technology is truly incredible, and we are excited to support CrisprBits harnessing this technology to develop high quality yet affordable and accessible solutions to improve human health. We look forward to working together to commercialize the products that are in the pipeline as well as develop new products. We strongly believe that this collaboration will lead to synergistic outcomes," said Vijay Alreja, founder and CEO, VJ Group.

Founded by Dr. Vijay Chandru, Sunil Arora, Dr. Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda in 2020, CrisprBits was started with a vision of developing high-quality healthcare solutions in diagnostics and gene editing that all Indians can afford. The company plans to extend its CRISPR-based diagnostics platform to point-of-care detection of pathogens and antimicrobial resistance genes associated with hospital-acquired infections. The company also developed OmiCrisp, a CRISPR- based test to detect SARS-CoV2 and to determine whether it is an Omicron or non-omicron variant. The test was developed with support and collaboration from the C-CAMP-InDx (Indigenisation of Diagnostics Program), an initiative supported by the Department of Biotechnology, Govt of India.

Saptak Bardhan

Former Trainee Writer

Former Trainee Writer
Marketing

6 Steps to a Simple and Effective Content Strategy

Strategy can be an intimidating word, but it doesn't have to be. Follow these simple guidelines to make sure your next piece of content — and every one thereafter — rings true to your brand.

Side Hustle

'Hustling Every Day': These Friends Started a Side Hustle With $2,500 Each — It 'Snowballed' to Over $500,000 and Became a Multimillion-Dollar Brand

Paris Emily Nicholson and Saskia Teje Jenkins had a 2020 brainstorm session that led to a lucrative business.

Business News

'I'm Shocked': Costco Customers Are Freaking Out About a Change to a Beloved Bakery Item

Costco customers are feeling burnt by a not-so-sweet switcheroo in the bakery department.

Growing a Business

Stop Chasing Subscribers — Start Making Money With These Newsletter Hacks

Here's how operators profit from newsletters by turning acquisition costs into revenue and leveraging one audience to build multiple assets.